{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:44Z","timestamp":1792239044722,"version":"4.4.0"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["CERTAINTY"],"award-info":[{"award-number":["CERTAINTY"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022790","name":"Hector Stiftung II","doi-asserted-by":"publisher","award":["ISOLA"],"award-info":[{"award-number":["ISOLA"]}],"id":[{"id":"10.13039\/501100022790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["microbone"],"award-info":[{"award-number":["microbone"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005676","name":"Fundaci\u00f3n Josep Carreras Contra la Leucemia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We explored single or consecutive chimeric antigen receptor (CAR) T and bispecific antibody (BsAb) treatment modalities as correlates of clinical outcomes, by complementary bias-correction analysis of a retrospective multicenter study of 640 patients with relapsed\/refractory multiple myeloma. The sequential use of both modalities seemed to yield the most favorable survival trajectories. Initiating treatment with CAR T [idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel), cesnicabtagene autoleucel (cesni-cel)] was associated with longer remission. However, mortality from early progression was similar regardless of initial modality, suggesting that resistance may negate initial efficacy difference. On the product level, the benefit of CAR T seemed to be driven by cilta-cel and cesni-cel, whereas BsAbs showed at least comparable outcomes with ide-cel. These exploratory findings highlight the critical importance of treatment sequencing in optimizing long-term outcomes and underscore the need for equitable and timely access to both modalities across healthcare systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this real-world cohort, initiating treatment with CAR T was associated with longer remission, and sequential immunotherapy incorporating both modalities yielded the most favorable outcomes. However, early treatment failure negated initial efficacy differences between modalities. These findings provide a rationale for prospective sequencing trials and equitable access to both treatments.<\/jats:p>\n                    <jats:p>See related commentary by Banerjee, p. 650<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0461","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:45:31Z","timestamp":1781289931000},"page":"697-710","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"first","affiliation":[{"name":"1Myeloma and Cellular Therapy Services, Memorial Sloan Kettering Cancer Center, New York, New York."},{"id":[{"id":"https:\/\/ror.org\/028hv5492","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Leipzig 2 Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, , Leipzig, Germany."},{"name":"3Fraunhofer Institute for Cellular Immunotherapy, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-9253","authenticated-orcid":false,"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00a6yph09","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Ostrava 4 Department of Hematooncology, , Ostrava, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01q9sj412","id-type":"ROR","asserted-by":"publisher"}],"name":"Inselspital 5 Universit\u00e4tsklinik f\u00fcr Medizinische Onkologie, , Universit\u00e4tsspital Bern, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-6583","authenticated-orcid":false,"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine I, University Hospital Dresden, Technical University Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4078-0653","authenticated-orcid":false,"given":"Anca-Maria","family":"Albici","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02na8dn90","id-type":"ROR","asserted-by":"publisher"}],"name":"Essen University Hospital 8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), , , Essen, Germany."},{"id":[{"id":"https:\/\/ror.org\/04mz5ra38","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Duisburg-Essen 8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), , , Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9800-1902","authenticated-orcid":false,"given":"Marcel","family":"Teichert","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02na8dn90","id-type":"ROR","asserted-by":"publisher"}],"name":"Essen University Hospital 8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), , , Essen, Germany."},{"id":[{"id":"https:\/\/ror.org\/04mz5ra38","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Duisburg-Essen 8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), , , Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-4185","authenticated-orcid":false,"given":"Uta Margareta","family":"Demel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"publisher"}],"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin 9 Department of Hematology, Oncology and Cancer Immunology, , Berlin, Germany."},{"name":"10Cluster of Excellence ImmunoPreCept, Berlin, Germany."},{"name":"11German Center for Translational Cancer Research (DKTK), National Center for Tumor Diseases (NCT), Partner Site Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-6947","authenticated-orcid":false,"given":"Antonia","family":"Busse","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"publisher"}],"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin 9 Department of Hematology, Oncology and Cancer Immunology, , Berlin, Germany."},{"name":"10Cluster of Excellence ImmunoPreCept, Berlin, Germany."},{"name":"11German Center for Translational Cancer Research (DKTK), National Center for Tumor Diseases (NCT), Partner Site Berlin, Berlin, Germany."},{"name":"12Max-Delbr\u00fcck-Center for Molecular Medicine, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9309-1659","authenticated-orcid":false,"given":"Marie Christine","family":"Wesener","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"publisher"}],"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin 9 Department of Hematology, Oncology and Cancer Immunology, , Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-523X","authenticated-orcid":false,"given":"Tobias A.W.","family":"Holderried","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xnwqx93","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Bonn 13 Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, , Bonn, Germany."},{"name":"14Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-1088","authenticated-orcid":false,"given":"Friederike","family":"Schmitz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01xnwqx93","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Bonn 13 Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, , Bonn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8858-981X","authenticated-orcid":false,"given":"Friedrich-Linus","family":"R\u00f6\u00dfiger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Erlangen 15 Department of Internal Medicine 5, Haematology and Oncology, , , Erlangen, Germany."},{"id":[{"id":"https:\/\/ror.org\/00f7hpc57","id-type":"ROR","asserted-by":"publisher"}],"name":"Friedrich-Alexander University of Erlangen-Nuremberg (FAU) 15 Department of Internal Medicine 5, Haematology and Oncology, , , Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-5839","authenticated-orcid":false,"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Erlangen 15 Department of Internal Medicine 5, Haematology and Oncology, , , Erlangen, Germany."},{"id":[{"id":"https:\/\/ror.org\/00f7hpc57","id-type":"ROR","asserted-by":"publisher"}],"name":"Friedrich-Alexander University of Erlangen-Nuremberg (FAU) 15 Department of Internal Medicine 5, Haematology and Oncology, , , Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2308-3959","authenticated-orcid":false,"given":"Michele","family":"Hoffmann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01q9sj412","id-type":"ROR","asserted-by":"publisher"}],"name":"Inselspital 5 Universit\u00e4tsklinik f\u00fcr Medizinische Onkologie, , Universit\u00e4tsspital Bern, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":false,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-476X","authenticated-orcid":false,"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02a2kzf50","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednic de Barcelona 16 , IDIBAPS, University of Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1699-9478","authenticated-orcid":false,"given":"Ben-Niklas","family":"Baermann","sequence":"additional","affiliation":[{"name":"17Onkologie Und Klinische Immunologie, Klinik F\u00fcr Haematologie, Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-8537","authenticated-orcid":false,"given":"Martin","family":"Stork","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qq1fp34","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Brno 18 Department of Internal Medicine, Hematology and Oncology, , Faculty of Medicine, Masaryk University, Brno, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3056-3130","authenticated-orcid":false,"given":"Alexandra","family":"Jungova","sequence":"additional","affiliation":[{"name":"19Department of Hematooncology, Charles University Hospital Pilsen, Pilsen, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-326X","authenticated-orcid":false,"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04qxnmv42","id-type":"ROR","asserted-by":"publisher"}],"name":"Palacky University Olomouc 20 Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, , Olomouc, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-8238","authenticated-orcid":false,"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[{"name":"214th Department of Internal Medicine e Hematology, University Hospital Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czech Republic."},{"id":[{"id":"https:\/\/ror.org\/024d6js02","id-type":"ROR","asserted-by":"publisher"}],"name":"Charles University 22 Faculty of Medicine in Hradec Kr\u00e1lov\u00e9, , Hradec Kr\u00e1lov\u00e9, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5283","authenticated-orcid":false,"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"231st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-7009","authenticated-orcid":false,"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00qq1fp34","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Brno 18 Department of Internal Medicine, Hematology and Oncology, , Faculty of Medicine, Masaryk University, Brno, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9392-8894","authenticated-orcid":false,"given":"Polona","family":"Novak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05njb9z20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Ljubljana 24 University Medical Center and Faculty of Medicine, , Ljubljana, Slovenia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0068-0686","authenticated-orcid":false,"given":"Klara","family":"Slajpah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05njb9z20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Ljubljana 24 University Medical Center and Faculty of Medicine, , Ljubljana, Slovenia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1535-9334","authenticated-orcid":false,"given":"Karla","family":"Rener","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05njb9z20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Ljubljana 24 University Medical Center and Faculty of Medicine, , Ljubljana, Slovenia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"publisher"}],"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin 9 Department of Hematology, Oncology and Cancer Immunology, , Berlin, Germany."},{"name":"10Cluster of Excellence ImmunoPreCept, Berlin, Germany."},{"name":"11German Center for Translational Cancer Research (DKTK), National Center for Tumor Diseases (NCT), Partner Site Berlin, Berlin, Germany."},{"name":"12Max-Delbr\u00fcck-Center for Molecular Medicine, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-3342","authenticated-orcid":false,"given":"Stephan","family":"Bohl","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001w7jn25","id-type":"ROR","asserted-by":"publisher"}],"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin 9 Department of Hematology, Oncology and Cancer Immunology, , Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4014-6030","authenticated-orcid":false,"given":"David","family":"Fandrei","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028hv5492","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Leipzig 2 Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, , Leipzig, Germany."},{"name":"3Fraunhofer Institute for Cellular Immunotherapy, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8463-5179","authenticated-orcid":false,"given":"Patrick","family":"Born","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028hv5492","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Leipzig 2 Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, , Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028hv5492","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Leipzig 2 Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Disease, , Leipzig, Germany."},{"name":"3Fraunhofer Institute for Cellular Immunotherapy, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02na8dn90","id-type":"ROR","asserted-by":"publisher"}],"name":"Essen University Hospital 8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), , , Essen, Germany."},{"id":[{"id":"https:\/\/ror.org\/04mz5ra38","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Duisburg-Essen 8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), , , Essen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-5850","authenticated-orcid":false,"given":"Irene","family":"Strassl","sequence":"additional","affiliation":[{"name":"25Division of Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Linz, Austria."},{"name":"26Medical Faculty, Johannes Kepler University Linz, Linz, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7407-5075","authenticated-orcid":false,"given":"Natalie","family":"Schub","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine, Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00a6yph09","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Ostrava 4 Department of Hematooncology, , Ostrava, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9487-5451","authenticated-orcid":false,"given":"Matja\u017e","family":"Sever","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05njb9z20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Ljubljana 24 University Medical Center and Faculty of Medicine, , Ljubljana, Slovenia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02a2kzf50","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednic de Barcelona 16 , IDIBAPS, University of Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01zgy1s35","id-type":"ROR","asserted-by":"publisher"}],"name":"University Medical Center Hamburg-Eppendorf 27 Department of Stem Cell Transplantation, , Hamburg, Germany."},{"name":"28Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026090303071697700_bib1","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090303071697700_bib2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2026090303071697700_bib3","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090303071697700_bib4","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026090303071697700_bib5","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/s1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026090303071697700_bib6","doi-asserted-by":"publisher","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026090303071697700_bib7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jcyt.2024.02.007","article-title":"Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)","volume":"26","author":"Sanchez-Guijo","year":"2024","journal-title":"Cytotherapy"},{"key":"2026090303071697700_bib8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jval.2022.12.014","article-title":"Financing and reimbursement of approved advanced therapies in several European countries","volume":"26","author":"Iglesias-L\u00f3pez","year":"2023","journal-title":"Value Health"},{"key":"2026090303071697700_bib9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090303071697700_bib10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"2026090303071697700_bib11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026090303071697700_bib12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090303071697700_bib13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090303071697700_bib14","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"Hemasphere"},{"key":"2026090303071697700_bib15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026090303071697700_bib16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-025-01254-4","article-title":"Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients","volume":"15","author":"Chunara","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026090303071697700_bib17","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1002\/hem3.70114","article-title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Hemasphere"},{"key":"2026090303071697700_bib18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","article-title":"Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients","volume":"108","author":"Gagelmann","year":"2023","journal-title":"Haematologica"},{"key":"2026090303071697700_bib19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026090303071697700_bib20","volume-title":"TECVAYLI\u00ae monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide","author":"Johnson & Johnson","year":"2026"},{"key":"2026090303071697700_bib21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026090303071697700_bib22","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"2026090303071697700_bib23","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"key":"2026090303071697700_bib24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","article-title":"mstate: an R package for the analysis of competing risks and multi-state models","volume":"38","author":"de Wreede","year":"2011","journal-title":"J Stat Softw"},{"key":"2026090303071697700_bib25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1191\/0962280202SM276ra","article-title":"Multi-state models for event history analysis","volume":"11","author":"Andersen","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"2026090303071697700_bib26","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"2026090303071697700_bib27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2026090303071697700_bib28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jval.2017.07.008","article-title":"Accounting for uncertainty in decision analytic models using rank preserving structural failure time modeling: application to parametric survival models","volume":"21","author":"Bennett","year":"2018","journal-title":"Value Health"},{"key":"2026090303071697700_bib29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s13063-023-07412-y","article-title":"Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use","volume":"24","author":"Prasad","year":"2023","journal-title":"Trials"},{"key":"2026090303071697700_bib30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/17407745251405136","article-title":"A note on rank-preserving structural failure time models to account for crossover","volume":"23","author":"Torres-Saavedra","year":"2026","journal-title":"Clin Trials"},{"key":"2026090303071697700_bib31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0272989X18765175","article-title":"A validation study of the rank-preserving structural failure time model: confidence intervals and unique, multiple, and erroneous solutions","volume":"38","author":"Ouwens","year":"2018","journal-title":"Med Decis Making"},{"key":"2026090303071697700_bib32","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1002\/(sici)1097-0258(19991015)18:19&lt;2617::aid-sim187&gt;3.0.co;2-e","article-title":"Randomization-based methods for correcting for treatment changes: examples from the Concorde trial","volume":"18","author":"White","year":"1999","journal-title":"Stat Med"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0461\/3803475\/bcd-25-0461.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0461\/3821628\/bcd-25-0461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/697\/3824868\/bcd-25-0461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/697\/3824868\/bcd-25-0461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:07:24Z","timestamp":1788419244000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/5\/697\/787640\/Outcomes-of-CAR-T-cell-Therapy-and-Bispecific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0461","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}